Vice President Clinical Development, Solid Tumor Franchise at The Janssen Pharmaceutical Companies of Johnson & Johnson
The U.S. FDA has granted Breakthrough Therapy Designation for our targeted releasing system for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Patients with this form of bladder cancer often have limited treatment options, such as repeated BCG-treatments or radical cystectomy. At Johnson & Johnson Innovative Medicine, we remain committed to developing new treatment approaches to help address the many unmet needs of patients with bladder cancer. Learn more: https://bit.ly/46MfD3v #MyCompany #BladderCancer
Global Medical Head- at the Johnson & Johnson Innovative Medicine . Harvard University
8moWhat a unique advancement in early stage bladder